MCID: UTR037
MIFTS: 26

Uterine Corpus Sarcoma

Categories: Cancer diseases

Aliases & Classifications for Uterine Corpus Sarcoma

MalaCards integrated aliases for Uterine Corpus Sarcoma:

Name: Uterine Corpus Sarcoma 12 14 69
Sarcoma of Corpus Uteri 12
Sarcoma of Uterus 12

Classifications:



External Ids:

Disease Ontology 12 DOID:5165
NCIt 46 C6339
SNOMED-CT 64 254877001
UMLS 69 C0338113

Summaries for Uterine Corpus Sarcoma

Disease Ontology : 12 An uterine corpus cancer that is located in the muscles of the uterus or located in other tissues that support the uterus.

MalaCards based summary : Uterine Corpus Sarcoma, also known as sarcoma of corpus uteri, is related to uterus leiomyosarcoma and uterine sarcoma. An important gene associated with Uterine Corpus Sarcoma is SMUG1 (Single-Strand-Selective Monofunctional Uracil-DNA Glycosylase 1). The drugs Cisplatin and Doxorubicin have been mentioned in the context of this disorder. Affiliated tissues include the muscles of the uterus or, uterus and lung.

Related Diseases for Uterine Corpus Sarcoma

Diseases related to Uterine Corpus Sarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

# Related Disease Score Top Affiliating Genes
1 uterus leiomyosarcoma 11.1
2 uterine sarcoma 11.1
3 uterine carcinosarcoma 11.0
4 sarcoma 10.0
5 endometrial stromal sarcoma 10.0
6 embryonal rhabdomyosarcoma 9.8
7 rhabdomyosarcoma 9.8

Graphical network of the top 20 diseases related to Uterine Corpus Sarcoma:



Diseases related to Uterine Corpus Sarcoma

Symptoms & Phenotypes for Uterine Corpus Sarcoma

Drugs & Therapeutics for Uterine Corpus Sarcoma

Drugs for Uterine Corpus Sarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 177)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cisplatin Approved Phase 3,Phase 2 15663-27-1 2767 441203 84093
2
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
3
Ifosfamide Approved Phase 3,Phase 2,Phase 1 3778-73-2 3690
4
Paclitaxel Approved, Vet_approved Phase 3,Phase 2 33069-62-4 36314
5
Gemcitabine Approved Phase 3,Phase 2,Phase 1 95058-81-4 60750
6
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 38904 498142
7
Lenograstim Approved, Investigational Phase 3,Phase 2,Phase 1 135968-09-1
8
Mechlorethamine Approved, Investigational Phase 3,Phase 2,Phase 1 51-75-2 4033
9
Mesna Approved, Investigational Phase 3 3375-50-6 598
10
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
11
Methylphenidate Approved, Investigational Phase 3 20748-11-2, 113-45-1 4158
12
Morphine Approved, Investigational Phase 3 57-27-2 5288826
13
Bevacizumab Approved, Investigational Phase 3 216974-75-3
14
Cyproheptadine Approved Phase 3 129-03-3 2913
15
Histamine Approved, Investigational Phase 3 51-45-6, 75614-87-8 774
16
Dehydroepiandrosterone Approved, Investigational, Nutraceutical Phase 3 53-43-0 9860744
17
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703
18
Docetaxel Approved May 1996, Investigational Phase 3,Phase 2,Phase 1 114977-28-5 148124 9877265
19 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
20 Alkylating Agents Phase 3,Phase 2,Phase 1
21 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
22 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
23 Isophosphamide mustard Phase 3,Phase 2,Phase 1 0
24 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
25 Albumin-Bound Paclitaxel Phase 3,Phase 2
26 Antimitotic Agents Phase 3,Phase 2,Phase 1
27 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
28 Liver Extracts Phase 3,Phase 1,Phase 2
29 Anti-Infective Agents Phase 3,Phase 2,Phase 1
30 Antimetabolites Phase 3,Phase 2,Phase 1
31 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
32 Antiviral Agents Phase 3,Phase 2,Phase 1
33 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
34 Angiogenesis Inhibitors Phase 3,Phase 2,Phase 1
35 Angiogenesis Modulating Agents Phase 3,Phase 2,Phase 1
36 Adjuvants, Anesthesia Phase 3
37 Analgesics Phase 3,Phase 2,Phase 1
38 Analgesics, Opioid Phase 3
39 Anesthetics Phase 3
40 Anesthetics, General Phase 3
41 Anesthetics, Intravenous Phase 3
42 Central Nervous System Depressants Phase 3
43 Narcotics Phase 3
44 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1
45 Epoetin alfa Phase 3 113427-24-0
46 Adjuvants, Immunologic Phase 3,Phase 2,Phase 1
47 Endothelial Growth Factors Phase 3,Phase 2
48 Mitogens Phase 3,Phase 2
49 Gastrointestinal Agents Phase 3,Phase 2
50 Antibodies Phase 3,Phase 2

Interventional clinical trials:

(show top 50) (show all 118)

# Name Status NCT ID Phase Drugs
1 The Addition of Polychemotherapy to Adjuvant Radiotherapy in the Treatment of Non-Metastatic Uterine Sarcomas Unknown status NCT00162721 Phase 3 doxorubicin, ifosfamide, cisplatin
2 Hyperbaric Oxygen Therapy in Treating Long-Term Gastrointestinal Adverse Effects Caused by Radiation Therapy in Patients With Pelvic Cancer Unknown status NCT01087268 Phase 3
3 Laparoscopic Surgery or Standard Surgery in Treating Patients With Endometrial Cancer or Cancer of the Uterus Completed NCT00002706 Phase 3
4 Radiation Therapy or No Further Treatment Following Surgery in Treating Patients With Cancer of the Uterus Completed NCT00002459 Phase 3
5 Ifosfamide With or Without Paclitaxel in Treating Patients With Advanced, Refractory, or Recurrent Cancer of the Uterus Completed NCT00003128 Phase 3 ifosfamide;paclitaxel
6 Radiation Therapy Compared With Combination Chemotherapy in Treating Patients With Cancer of the Uterus Completed NCT00002546 Phase 3 cisplatin;ifosfamide
7 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
8 Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00002641 Phase 3 doxorubicin hydrochloride;ifosfamide;isolated perfusion
9 E-MOSAIC Electronic Tool to Monitor Symptoms Completed NCT00477919 Phase 3
10 Surgery With or Without Combination Chemotherapy in Treating Patients With Lung Metastases From Soft Tissue Sarcoma Completed NCT00002764 Phase 3 doxorubicin hydrochloride;ifosfamide
11 Ifosfamide or Doxorubicin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00003212 Phase 3 doxorubicin hydrochloride;ifosfamide
12 Short Course Vaginal Cuff Brachytherapy in Treating Patients With Stage I-II Endometrial Cancer Recruiting NCT03422198 Phase 3
13 Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery Active, not recruiting NCT01533207 Phase 3 Docetaxel;Doxorubicin Hydrochloride;Gemcitabine Hydrochloride
14 Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer Active, not recruiting NCT00954174 Phase 3 Carboplatin;Ifosfamide;Paclitaxel
15 Prasterone (Dehydroepiandrosterone) in Treating Postmenopausal Cancer Survivors With Vaginal Symptoms Active, not recruiting NCT01376349 Phase 3 prasterone
16 Gemcitabine Hydrochloride and Docetaxel With or Without Bevacizumab in Treating Patients With Advanced or Recurrent Uterine Leiomyosarcoma Terminated NCT01012297 Phase 3 Docetaxel;Gemcitabine Hydrochloride
17 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
18 Phase 1-2 Study of Onapristone in Patients With Progesterone Receptor Expressing Cancers Unknown status NCT02052128 Phase 1, Phase 2 onapristone
19 Temozolomide and Thalidomide in Treating Patients With Metastatic, Locally Advanced, or Unresectable Leiomyosarcoma Unknown status NCT00033709 Phase 2 temozolomide;thalidomide
20 Brostallicin or Doxorubicin as First-Line Therapy in Treating Patients With Relapsed, Refractory, or Metastatic Soft Tissue Sarcoma Unknown status NCT00410462 Phase 2 brostallicin;doxorubicin hydrochloride
21 Temozolomide in Treating Patients With Advanced Soft Tissue Sarcoma Unknown status NCT00003718 Phase 2 temozolomide
22 Nutritional Supplements in Improving Quality of Life During First-Line Chemotherapy in Patients With Metastatic Gynecological Cancer Unknown status NCT00905658 Phase 2
23 Chemotherapy in Treating Patients With Sarcoma of the Uterus Completed NCT00005643 Phase 2 pegylated liposomal doxorubicin hydrochloride
24 Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Completed NCT01637961 Phase 2 Alisertib
25 Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer Completed NCT01247571 Phase 2 Pazopanib Hydrochloride
26 Ixabepilone in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Previously Treated With Chemotherapy Completed NCT01220609 Phase 2 Ixabepilone
27 Gemcitabine and Docetaxel in Treating Patients With Recurrent or Persistent Uterine Cancer Completed NCT00114218 Phase 2 Gemcitabine Hydrochloride;Docetaxel
28 Combination Chemotherapy and Filgrastim or Pegfilgrastim in Treating Patients With Recurrent or Persistent Cancer of the Uterus Completed NCT00031629 Phase 2 Docetaxel;Gemcitabine Hydrochloride
29 Thalidomide in Treating Patients With Recurrent or Persistent Carcinosarcoma of the Uterus Completed NCT00025506 Phase 2 Thalidomide
30 Thalidomide in Treating Patients With Recurrent or Persistent Cancer of the Uterus Completed NCT00025220 Phase 2 Thalidomide
31 Sunitinib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Completed NCT00378911 Phase 2 sunitinib malate
32 Imatinib Mesylate in Treating Patients With Recurrent or Persistent Uterine Cancer Completed NCT00075400 Phase 2 imatinib mesylate
33 Multicenter Trial With PegLiposomal Doxorubicin and Carboplatin Combination Chemotherapy in Gynecological Sarcomas and Mixed Epithelial-Mesenchymal Tumors Completed NCT00815945 Phase 2 PegLiposomal Doxorubicin;Carboplatin
34 Sorafenib in Treating Patients With Advanced or Recurrent Uterine Cancer Completed NCT00238121 Phase 2 sorafenib tosylate
35 Paclitaxel and Carboplatin in Treating Patients With Persistent or Recurrent Stage III or Stage IV Uterine Cancer Completed NCT00112489 Phase 2 carboplatin;paclitaxel
36 Docetaxel, Gemcitabine, and Filgrastim (G-CSF) or Pegfilgrastim in Treating Patients With Advanced, Persistent, or Recurrent Uterine Leiomyosarcoma Completed NCT00101127 Phase 2 docetaxel;gemcitabine hydrochloride
37 Trabectedin in Treating Patients With Advanced, Persistent, or Recurrent Leiomyosarcoma of the Uterus Completed NCT00379145 Phase 2 trabectedin
38 Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma Completed NCT01154452 Phase 1, Phase 2 Gamma-Secretase Inhibitor RO4929097;Vismodegib
39 Dolastatin 10 in Treating Patients With Recurrent or Metastatic Soft Tissue Sarcoma Completed NCT00003778 Phase 2 dolastatin 10
40 Therapeutic Angiotensin-(1-7) in Treating Patients With Metastatic Sarcoma That Cannot Be Removed By Surgery Completed NCT01553539 Phase 2 therapeutic angiotensin-(1-7)
41 Stereotactic Radiosurgery Using CyberKnife in Treating Women With Advanced or Recurrent Gynecological Malignancies Completed NCT01079832 Phase 2
42 AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00659360 Phase 2 saracatinib
43 Ziv-aflibercept in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissue Sarcoma Completed NCT00390234 Phase 2 ziv-aflibercept
44 Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma Completed NCT00245102 Phase 2 sorafenib tosylate
45 Thalidomide in Treating Patients With Gynecologic Sarcomas Completed NCT00006005 Phase 2 thalidomide
46 Liposomal Doxorubicin and Carboplatin in Treating Patients With Gynecologic Cancer Completed NCT00032162 Phase 1, Phase 2 carboplatin;pegylated liposomal doxorubicin hydrochloride
47 Chemotherapy in Treating Patients With Advanced Sarcoma Completed NCT00002526 Phase 2 doxorubicin hydrochloride;ifosfamide
48 Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas Completed NCT00474994 Phase 2 sunitinib malate
49 Gemcitabine With or Without Docetaxel as Second-Line Therapy in Treating Patients With Metastatic or Relapsed, Unresectable Uterine or Soft Tissue Leiomyosarcoma Completed NCT00227669 Phase 2 docetaxel;gemcitabine hydrochloride
50 High-dose ICE With Amifostine Completed NCT00003657 Phase 2 Amifostine;Carboplatin;Etoposide;Ifosfamide

Search NIH Clinical Center for Uterine Corpus Sarcoma

Genetic Tests for Uterine Corpus Sarcoma

Anatomical Context for Uterine Corpus Sarcoma

The Foundational Model of Anatomy Ontology organs/tissues related to Uterine Corpus Sarcoma:

18
The Muscles Of The Uterus Or

MalaCards organs/tissues related to Uterine Corpus Sarcoma:

38
Uterus, Lung, Brain, T Cells, Endothelial, Prostate, Kidney

Publications for Uterine Corpus Sarcoma

Articles related to Uterine Corpus Sarcoma:

# Title Authors Year
1
Genomic landscape of endometrial stromal sarcoma of uterus. ( 26429873 )
2015
2
Endometrial stromal sarcoma of uterus with metastasis to the lung and brain. ( 22987911 )
2012
3
Endometrial stromal sarcoma of uterus. ( 21820965 )
2011
4
Mixed low grade and high grade endometrial stromal sarcoma of uterus: differences on immunohistochemistry and chromosome in situ hybridisation. ( 8813967 )
1996

Variations for Uterine Corpus Sarcoma

Expression for Uterine Corpus Sarcoma

Search GEO for disease gene expression data for Uterine Corpus Sarcoma.

Pathways for Uterine Corpus Sarcoma

GO Terms for Uterine Corpus Sarcoma

Sources for Uterine Corpus Sarcoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....